Advances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes

References

• International Diabetes Federation [webpage on the Internet]IDF Diabetes Atlas7th edBrusselsThe Federation2015 Available from: http://www.Diabetesatlas.org/Resources/2015-Atlas.htmlAccessed October 17, 2016
   Google Scholar
• Emerging Risk Factors CollaborationSeshasaiSRKKaptogeSDiabetes mellitus, fasting glucose, and risk of cause-specific deathN Engl J Med2011364982984121366474
   PubMed Web of Science ®Google Scholar
• LauDCWDhillonBYanHSzmitkoPEVermaSAdipokines: molecular links between obesity and atheroslcerosisAm J Physiol Heart Circ Physiol20052885H2031H204115653761
   PubMed Web of Science ®Google Scholar
• Emerging Risk Factors CollaborationDi AngelantonioEKaptogeSAssociation of cardiometabolic multimorbidity with mortalityJAMA20153141526026151266
   PubMed Web of Science ®Google Scholar
• Action to Control Cardiovascular Risk in Diabetes Study GroupGersteinHCMillerMEEffects of intensive glucose lowering in type 2 diabetesN Engl J Med2008358242545255918539917
   PubMed Web of Science ®Google Scholar
• Advance Collaborative GroupPatelAMacMahonSIntensive blood glucose control and vascular outcomes in patients with type 2 diabetesN Engl J Med2008358242560257218539916
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) GroupIntensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)Lancet199835291318378539742976
   PubMed Web of Science ®Google Scholar
• DuckworthWAbrairaCMoritzTGlucose control and vascular complications in veterans with type 2 diabetesN Engl J Med2009360212913919092145
   PubMed Web of Science ®Google Scholar
• HolmanRRSourijHCaliffRMCardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetesLancet201438399332008201724910232
   PubMed Web of Science ®Google Scholar
• SonessonCJohanssonPAJohnssonEGause-NilssonICardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysisCardiovasc Diabetol20161513726895767
   PubMed Web of Science ®Google Scholar
• StamlerJVaccaroONeatonJDWentworthDDiabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention TrialDiabetes Care19931624344448432214
   PubMed Web of Science ®Google Scholar
• World Heart Federation [webpage on the Internet]Cardiovascular Disease Risk Factors – DiabetesWorld Heart Federation Available from: http://www.World-Heart-Federation.org/Cardiovascular-Health/Cardiovascular-Disease-Risk-Factors/Diabetes/Accessed October 17, 2016
   Google Scholar
• JeerakathilTJohnsonJASimpsonSHMajumdarSRShort-term risk for stroke is doubled in persons with newly treated type 2 diabetes compared with persons without diabetesStroke20073861739174317478738
   PubMed Web of Science ®Google Scholar
• Stark CasagrandeSFradkinJESaydahSHRustKFCowieCCThe prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988–2010Diabetes Care20133682271227923418368
   PubMed Web of Science ®Google Scholar
• American Diabetes AssociationStandards of medical care in diabetes – 2015Diabetes Care201538suppl 1S1S99
   PubMed Web of Science ®Google Scholar
• PiepoliMFHoesAWAgewallS2016 European Guidelines on cardiovascular disease prevention in clinical practiceEur Heart J201637292315238127222591
   PubMed Web of Science ®Google Scholar
• CollaboratorsCTTCEfficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysisLancet2008371960711712518191683
   PubMed Web of Science ®Google Scholar
• Blood Pressure Lowering Treatment Trialists’ CollaborationSundströmJArimaHBlood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient dataLancet2014384994359159825131978
   PubMed Web of Science ®Google Scholar
• EmdinCARahimiKNealBCallenderTPerkovicVPatelABlood pressure lowering in type 2 diabetes: a systematic review and meta-analysisJAMA2015313660361525668264
   PubMed Web of Science ®Google Scholar
• Control GroupTurnbullFMAbrairaCIntensive glucose control and macrovascular outcomes in type 2 diabetesDiabetologia200952112288229819655124
   PubMed Web of Science ®Google Scholar
• BergenstalRMBaileyCJKendallDMType 2 diabetes: assessing the relative risks and benefits of glucose-lowering medicationsAm J Med20101234374.e9374.e18
   Web of Science ®Google Scholar
• InzucchiSEZinmanBWannerCSGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trialsDiab Vasc Dis Res20151229010025589482
   PubMed Web of Science ®Google Scholar
• AACEACE [webpage on the Internet]Comprehensive Type 2 Diabetes Management AlgorithmAACEACE Available from: https://www.aace.com/publications/algorithmAccessed October 17, 2016
   Google Scholar
• Center for Drug Evaluation and Research (CDER)Diabetes Mellitus – Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes [Guidance for Industry]Silver Spring, MDCenter for Drug Evaluation and Research (CDER)2008 Available from: http://www.Fda.Gov/Downloads/Drugs/Guidancecompli-anceregulatoryinformation/Guidances/Ucm071627.pdfAccessed October 17, 2016
   Google Scholar
• ZinmanBWannerCLachinJMEmpagliflozin, cardiovascular outcomes, and mortality in type 2 diabetesN Engl J Med2015373222117212826378978
   PubMed Web of Science ®Google Scholar
• GaedePLund-AndersenHParvingH-HPedersenOEffect of a multifactorial intervention on mortality in type 2 diabetesN Engl J Med2008358658059118256393
   PubMed Web of Science ®Google Scholar
• HirshbergBKatzACardiovascular outcome studies with novel antidiabetes agents: scientific and operational considerationsDiabetes Care201336suppl 2S253S25823882054
   PubMed Web of Science ®Google Scholar
• LincoffAMWolskiKNichollsSJNissenSEPioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trialsJAMA2007298101180118817848652
   PubMed Web of Science ®Google Scholar
• LokeYKKwokCSSinghSComparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studiesBMJ2011342d1309d130921415101
   PubMed Web of Science ®Google Scholar
• European Medicines AgencyGuideline on Clinical Investigation of Medicinal Products in the Treatment or Prevention of Diabetes MellitusLondonCommittee for Medicinal Products for Human Use (CHMP)2012 CPMP/EWP/1080/00. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500129256.pdfAccessed October 17, 2016
   Google Scholar
• GeigerMJMehtaCRick TurnerJClinical development approaches and statistical methodologies to prospectively assess the cardiovascular risk of new antidiabetic therapies for type 2 diabetesTher Innov Regul Sci20154915064
   PubMed Web of Science ®Google Scholar
• JohansenOEInterpretation of cardiovascular outcome trials in type 2 diabetes needs a multiaxial approachWorld J Diab20156910921096
   PubMedGoogle Scholar
• SciricaBMBhattDLBraunwaldESaxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitusN Engl J Med2013369141317132623992601
   PubMed Web of Science ®Google Scholar
• WhiteWBCannonCPHellerSRAlogliptin after acute coronary syndrome in patients with type 2 diabetesN Engl J Med2013369141327133523992602
   PubMed Web of Science ®Google Scholar
• GreenJBBethelMAArmstrongPWEffect of sitagliptin on cardiovascular outcomes in type 2 diabetesN Engl J Med2015373323224226052984
   PubMed Web of Science ®Google Scholar
• US Food and Drug AdministrationDiabetes Medications Containing Saxagliptin and Alogliptin: Drug Safety Communication – Risk of Heart FailureSilver Spring, MDSafety Information and Adverse Event Reporting Program2016 Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm494252.htmAccessed May 5, 2016
   Google Scholar
• PfefferMAClaggettBDiazRLixisenatide in patients with type 2 diabetes and acute coronary syndromeN Engl J Med2015373232247225726630143
   PubMed Web of Science ®Google Scholar
• MarsoSPDanielsGHBrown-FrandsenKLiraglutide and cardiovascular outcomes in type 2 diabetesN Engl J Med2016375431132227295427
   PubMed Web of Science ®Google Scholar
• TuckerME webpage on the InternetTop-Line Data Show CV Benefit for Liraglutide in Type 2 DiabetesMedscape2016 Available from: http://www.medscape.com/viewarticle/859905Accessed May 5, 2016
   Google Scholar
• HachTGerichJSalsaliAEmpagliflozin improves glycemic parameters and cardiovascular risk factors in patients with type 2 diabetes (T2DM): pooled data from four pivotal phase III trialsDiabetol Stoffwechsel20149suppl01
   Google Scholar
• FitchettDZinmanBWannerCHeart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trialEur Heart J201637191526153426819227
   PubMed Web of Science ®Google Scholar
• WannerCThe American College of Cardiology Meeting 2016 (ACC.16) Oral PresentationChicago, IL2016
   Google Scholar
• CherneyDZIPerkinsBASoleymanlouNThe renal hemodynamic effect of SGLT2 inhibition in patients with type 1 diabetesCirculation2014129558759724334175
   PubMed Web of Science ®Google Scholar
• Abdul-GhaniMDel PratoSChiltonRDeFronzoRASGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG OUTCOME StudyDiabetes Care201639571772527208375
   PubMed Web of Science ®Google Scholar
• GrossJLde AzevedoMJSilveiroSPCananiLHCaramoriMLZelmanovitzTDiabetic nephropathy: diagnosis, prevention, and treatmentDiabetes Care200528116417615616252
   PubMed Web of Science ®Google Scholar
• BrennerBMCooperMEde ZeeuwDEffects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathyN Engl J Med20013451286186911565518
   PubMed Web of Science ®Google Scholar
• LewisEJHunsickerLGClarkeWRRenoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetesN Engl J Med20013451285186011565517
   PubMed Web of Science ®Google Scholar
• WannerCInzucchiSELachinJMEmpagliflozin and progression of kidney disease in type 2 diabetesN Engl J Med2016375432333427299675
   PubMed Web of Science ®Google Scholar
• European Medicines AgencyJardiance Summary of Product CharacteristicsLondonEuropean Medicines Agency2016 EMEA/H/C/002677. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/SGLT2_inhibitors__20/European_Commission_final_decision/WC500206515.pdfAccessed June 14, 2016
   Google Scholar
• US Food and Drug Administration [webpage on the Internet]Canagliflozin (Invokana, Invokamet) and Dapagliflozin (Farxiga, Xigduo XR): Drug Safety Communication – Strengthened Kidney Warnings [Safety Alert]Silver Spring, MDSafety Information and Adverse Event Reporting Program2016 Available from: http://www.Fda.Gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm506554.htmAccessed June 15, 2016
   Google Scholar
• WattsNBBilezikianJPUsiskinKCANVAS – CANagliflozin cardiovascular Assessment Study. NCT01032629J Clin Endocrinol Metab2016101115716626580237
   PubMed Web of Science ®Google Scholar
• AstraZenecaMulticentre Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events (DECLARE-TIMI58) Available from: https://clinicaltrials.gov/ct2/show/NCT01730534?term=NCT01730534&rank=1. NLM identifier: NCT01730534Accessed October 17, 2016
   Google Scholar
• NauckMAUpdate on developments with SGLT2 inhibitors in the management of type 2 diabetesDrug Des Devel Ther2014813351380
   PubMed Web of Science ®Google Scholar
• US Food and Drug AdministrationNDA 204042: Invokana (Canagliflozin) Tablets [Briefing Document]Silver Spring, MDEndocrinologic and Metabolic Drugs Advisory Committee2013 Available from: http://www.Fda.Gov/Downloads/%20AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/%20EndocrinologicandMetabolicDrugsAdvisory-Committee/UCM334550.pdfAccessed May 6, 2016
   Google Scholar
• DziubaJAlperinPRacketaJModeling effects of SGLT – 2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomesDiabetes Obes Metab201416762863524443793
   PubMed Web of Science ®Google Scholar
• GilbertREKrumHHeart failure in diabetes: effects of antihyperglycaemic drug therapyLancet201538599822107211726009231
   PubMed Web of Science ®Google Scholar
• DickerDDPP-4 inhibitorsDiabetes Care201134suppl 2S276S27821525468
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and PreventionNational Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011 ChapAtlanta, GAU.S. Department of Health and Human Services, Centers for Disease Control and Prevention2011 Available from: http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdfAccessed October 17, 2016
   Google Scholar
• HolmanRRPaulSKBethelMAMatthewsDRNeilHAW10-year follow-up of intensive glucose control in type 2 diabetesN Engl J Med2008359151577158918784090
   PubMed Web of Science ®Google Scholar
• ShaSPolidoriDFarrellKPharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover studyDiabetes Obes Metab201517218819725421015
   PubMed Web of Science ®Google Scholar
• MunirKMDavisSNDifferential pharmacology and clinical utility of empagliflozin in type 2 diabetesClin Pharmacol20168193427186083
   PubMedGoogle Scholar
• US National Institutes of HealthClinical trials Available from. https://clinicaltrials.govAccessed October 17, 2016
   Google Scholar